Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 842 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR More Than One in 10 Patients With Lung Cancer Do Not... March 17, 2021 Υποτροπιάζων ή μεταστατικός καρκίνος κεφαλής και τραχήλου: Νέα δεδομένα αναμένεται ότι... June 24, 2019 EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the... December 17, 2021 Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App September 18, 2021 Load more HOT NEWS Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with... Trial Results Highlight Changing Lung Cancer Treatment Landscape KRASG12D-Mutated NSCLC is Subtype with Distinct Co-mutations, a Colder Immune Microenvironment,...
